1854-1855 / 2001
T
The MSKCC experience ; the 2013 paper
•
Brachytherapy.
2013 Dec 24. S1538-4721
A Ph II t d f l
hi h d t
•
ase s u y o sa vage g - ose-ra e
brachytherapy for the treatment of locally
recurrent prostate cancer after definitive
t
l b
di th
ex erna eam ra o erapy.
•
Yamada Y
1
,
Kollmeier MA
2
,
Pei X
2
,
Kan CC
2
,
Cohen GN
3
,
Donat SM
4
,
Cox BW
2
,
Zelefsky MJ
2
.
1
D t
t f R di ti O l
M i l Sl
K tt i
•
epar men o a a on nco ogy, emor a oan- e er ng
Cancer Center, New York, NY.
•
METHODS:
•
Forty two patients with biopsy proven recurrence were
-
-
enrolled on a Phase II study of salvage HDR monotherapy
using iridium-192. Median pretreatment EBRT dose was 8100 cGy
(6840-8640 cGy) and the median time from completion of EBRT to
l
HDR
h
Th
l
i i d f
sa vage
was 73 mont s
.
e protoco prescr pt on ose o
3200 cGy was delivered in four fractions over 30 hours in a
single insertion.
Median follow up after salvage HDR was 36 months
(6-67 months).